Modified BFM-90 regimen greatly improves treatment outcomes of chinese childhood and adolescent lymphoblastic lymphoma
Sun, X-fei.; Zhen, Z-jun.; Liu, D-geng.; Xia, Z-jun.; Huang, H-qiang.; Zhang, L.; Zhou, Z-mei.; Li, Y-hong.; Xia, Y.; Ling, J-yu.; Guan, Z-zhen.
Zhonghua Zhong Liu Za Zhi 29(1): 58-61
2007
ISSN/ISBN: 0253-3766 PMID: 17575697 Document Number: 610339
Objective This study was designed to evaluate the efficacy and toxicity of modified BFM-90 regimen originated from Germany authors in the treatment of Chinese childhood and adolescent lymphoblastic lymphoma. Methods Thirty-six untreated lymphoblastic lymphoma patients aged from 3 to 18 years were included, with I patient in stage 11, 9 in stage III and 26 in stage IV. Of these 36 patients, 28 (77.7%) were diagnosed as T cell phenotype, 26 (72.2%) were found to have mediastinal mass, 21 (58.3%) had bone marrow involvement. All patients received chemotherapy of modified BFM-90 regimen consisting of induction remission, central nerve system prophylaxis, re-induction remission and maintenance therapy. Total treatment duration was two years. The difference from standard BFM-90 is that we omitted cranial radiotherapy but gave regular high dose methotrexate (MTX) iv infusion and intrathecal MTX therapy during maintenance therapy period. Kaplan-Meier method was used to evaluate survival rate. Results Of 36 patients, 32 (88%) achieved complete remission (CR), 1 (2.7%) partial remission ( PR) with an overall response rate of 90.7%. One patient had disease progression (DP). Two patients received autologous stem cell transplantation at CRI, and two patients received radiotherapy to mediastinum. Totally, 5 patients relapsed, while 2 of them were still alive after salvage chemotherapy. The other 3 died of tumor progression. Two patients died during induction remission, I of fungal septicemia, the other of cerebral hemorrhage; one PR and one DP patient died of disease, therefore, totally 7 patients died at last. Median follow-up time was 28 months. Overall three-year survival rate was 78.3% The major toxicity was myelosuppression. Conclusion Modified BFM-90 protocol can improve the efficacy and survival of Chinese childhood and adolescent lymphoblastic lymphoma with tolerable toxicity. However, this modified protocol should only be used in experienced cancer center or hematological unit.